These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 23375281

  • 1. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
    Sureshkumar KK, Hussain SM, Thai NL, Marcus RJ.
    Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
    [Abstract] [Full Text] [Related]

  • 2. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
    Sureshkumar KK, Thai NL, Hussain SM, Ko TY, Marcus RJ.
    Transplantation; 2012 Apr 27; 93(8):799-805. PubMed ID: 22290269
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alemtuzumab induction in deceased donor kidney transplantation.
    Huang E, Cho YW, Hayashi R, Bunnapradist S.
    Transplantation; 2007 Oct 15; 84(7):821-8. PubMed ID: 17984833
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Impact of steroid maintenance on the outcomes in first-time deceased donor kidney transplant recipients: Analysis by induction type.
    Sureshkumar KK, Hussain SM, Thai NL, Ko TY, Nashar K, Marcus RJ.
    World J Transplant; 2014 Sep 24; 4(3):188-95. PubMed ID: 25346892
    [Abstract] [Full Text] [Related]

  • 9. Effect of induction agent on posttransplant outcomes in deceased donor kidney transplant recipients: influence of race.
    Hussain SM, Sureshkumar KK, Ko TY, Marcus RJ.
    Transplant Proc; 2013 Sep 24; 45(1):119-21. PubMed ID: 23283292
    [Abstract] [Full Text] [Related]

  • 10. Influence of steroid maintenance on the outcomes in deceased donor kidney transplant recipients experiencing delayed graft function.
    Tangirala B, Marcus RJ, Hussain SM, Sureshkumar KK.
    Indian J Nephrol; 2013 Nov 24; 23(6):403-8. PubMed ID: 24339515
    [Abstract] [Full Text] [Related]

  • 11. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC.
    Cochrane Database Syst Rev; 2017 Jan 11; 1(1):CD004759. PubMed ID: 28073178
    [Abstract] [Full Text] [Related]

  • 12. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis.
    Sampaio MS, Chopra B, Sureshkumar KK.
    Transplantation; 2017 Oct 11; 101(10):2527-2535. PubMed ID: 28475563
    [Abstract] [Full Text] [Related]

  • 13. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
    Sureshkumar KK, Thai NL, Marcus RJ.
    Transplant Proc; 2012 Jun 11; 44(5):1262-4. PubMed ID: 22663997
    [Abstract] [Full Text] [Related]

  • 14. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 11; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 11; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 16. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.
    Transplantation; 2009 Oct 15; 88(7):904-10. PubMed ID: 19935462
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D.
    Transplant Proc; 2010 Oct 15; 42(6):2006-8. PubMed ID: 20692393
    [Abstract] [Full Text] [Related]

  • 18. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
    Kuo HT, Huang E, Emami S, Pham PT, Wilkinson AH, Danovitch GM, Bunnapradist S.
    Transplantation; 2012 Mar 15; 93(5):493-502. PubMed ID: 22306574
    [Abstract] [Full Text] [Related]

  • 19. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE, Enderby CY, Gonwa TA, Wadei HM.
    Clin Transplant; 2015 Jul 15; 29(7):573-80. PubMed ID: 25711849
    [Abstract] [Full Text] [Related]

  • 20. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.
    Riad S, Jackson S, Chinnakotla S, Verghese P.
    Pediatr Transplant; 2021 Aug 15; 25(5):e13928. PubMed ID: 33314638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.